Annunziata, G.; Scala, E.; Mercurio, L.; Sanna, L.; Dattolo, A.; Pagnanelli, G.; Lolli, M.G.; Belli, R.; Moretta, G.; Savastano, S.;
et al. Anti-IL-17 and Anti-IL-23 Therapies Modulate Serum Biomarkers of Intestinal Dysbiosis and Oxidative Stress Linked to Cardiovascular Risk in Patients with Psoriasis. Life 2025, 15, 1703.
https://doi.org/10.3390/life15111703
AMA Style
Annunziata G, Scala E, Mercurio L, Sanna L, Dattolo A, Pagnanelli G, Lolli MG, Belli R, Moretta G, Savastano S,
et al. Anti-IL-17 and Anti-IL-23 Therapies Modulate Serum Biomarkers of Intestinal Dysbiosis and Oxidative Stress Linked to Cardiovascular Risk in Patients with Psoriasis. Life. 2025; 15(11):1703.
https://doi.org/10.3390/life15111703
Chicago/Turabian Style
Annunziata, Giuseppe, Emanuele Scala, Laura Mercurio, Luca Sanna, Anna Dattolo, Gianluca Pagnanelli, Maria Grazia Lolli, Roberta Belli, Gaia Moretta, Silvia Savastano,
and et al. 2025. "Anti-IL-17 and Anti-IL-23 Therapies Modulate Serum Biomarkers of Intestinal Dysbiosis and Oxidative Stress Linked to Cardiovascular Risk in Patients with Psoriasis" Life 15, no. 11: 1703.
https://doi.org/10.3390/life15111703
APA Style
Annunziata, G., Scala, E., Mercurio, L., Sanna, L., Dattolo, A., Pagnanelli, G., Lolli, M. G., Belli, R., Moretta, G., Savastano, S., Muscogiuri, G., Maisto, M., Ciampaglia, R., Piccolo, V., Tenore, G. C., Albanesi, C., Madonna, S., & Barrea, L.
(2025). Anti-IL-17 and Anti-IL-23 Therapies Modulate Serum Biomarkers of Intestinal Dysbiosis and Oxidative Stress Linked to Cardiovascular Risk in Patients with Psoriasis. Life, 15(11), 1703.
https://doi.org/10.3390/life15111703
